38213-69-3

Usage

Uses

Used in Pharmaceutical Industry:
BIS(MALTOLATO)OXOVANADIUM(IV) is used as an insulin mimic for its ability to lower blood glucose levels. It has shown potential as an oral glucose-lowering drug, which could provide a non-invasive alternative to traditional insulin injections for patients with diabetes.
Used in Research and Development:
In the field of research and development, BIS(MALTOLATO)OXOVANADIUM(IV) can be utilized as a starting point for the development of new drugs and therapies targeting diabetes and other related metabolic disorders. Its unique chemical properties and insulin-mimicking capabilities make it an interesting compound for further study and potential application in the medical field.
Used in Material Science:
Due to its dark purple solid form, BIS(MALTOLATO)OXOVANADIUM(IV) may also find applications in material science, particularly in the development of pigments or dyes for various industries such as textiles, plastics, and printing. Its unique color properties could be harnessed for the creation of new colorants or for improving the performance of existing ones.

Pharmaceutical Applications

Bis(maltolato)oxovanadium (BMOV) has proven itself as a successful antidiabetic agent when tested in animalmodels. Nevertheless, only very little is known about its mode of action. It is believed that BMOV acts as a competitive and reversible inhibitor of the enzyme protein tyrosine phosphatase (PTP). As previously mentioned, BMOV is believed to be a potent and competitive inhibitor of the PTP1B activity and additionally seem to support the autophosphorylation of the insulin receptor leading to an increased sensitivity towards insulin. Research has shown that varying the organic ligand has an influence on the effectiveness and bioavailability of the resulting vanadium compound. It is believed that factors such as absorption, tissue uptake and distribution are affected most. Interestingly enough, X-ray crystal data of PTP1B soaked with BMOV showed only vanadate [V(+V)O43?] at the active site. This would emphasise that the organic ligands are only carriers of the active compound and play no role in the enzyme inhibition itself. Furthermore, in aqueous solution, V(IV) is rapidly and reversibly oxidised to V(V), supporting the possible formation of vanadate.

InChI:InChI=1/2C6H6O3.O.V/c2*1-4-6(8)5(7)2-3-9-4;;/h2*2-3,8H,1H3;;/q;;;+2/p-2/r2C6H6O3.OV/c2*1-4-6(8)5(7)2-3-9-4;1-2/h2*2-3,8H,1H3;/q;;+2/p-2

Upstream product

• 266339-51-9 tris(maltolato)vanadium(III) 
• 118-71-8 Maltol 

Relevant academic research and scientific papers

Vanadium speciation by XANES spectroscopy: A three-dimensional approach

A library of X-ray absorption near-edge structure (XANES) spectroscopic data for VV, VIV and VIII complexes with a broad range of biologically relevant ligand has been used to demonstrate that three-dimensional plots of key XANES parameters (pre-edge and edge energies; pre-edge and white line intensities) can be used for the prediction of V oxidation states and coordination numbers in biological or environmental matrices. The reliability of the technique has been demonstrated by re-analysis of the published XANES data for a VV-dependent bromoperoxidase.

A MAGNETIC RESONANCE IMAGING METHOD USING VANADYL-BASED CONTRAST AGENTS

A new, clinically applicable magnetic resonance imaging (MRI) method has been developed for in vivo imaging of a population of cells in a subject based on a class of paramagnetic divalent vanadyl-based contrast agents. The method includes administering to a subject a VO2+-based contrast agent and monitoring distribution of the VO2+-based contrast agent in the subject using magnetic resonance imaging.

Insulin-enhancing vanadium(III) complexes

Simple, high-yield, large-scale syntheses of the V(III) complexes tris(maltolato)vanadium(III), V(ma)3, tris(ethylmaltolato)vanadium(III), V(ema)3, tris(kojato)vanadium(III) monohydrate, V(koj)3·H2O, and tris(1,

Reaction chemistry of BMOV, bis(maltolato)oxovanadium(IV) - A potent insulin mimetic agent

The reaction chemistry of the potent insulin-mimetic agent bis(maltolato)oxovanadium(IV) (abbreviated BMOV or VO(ma)2) is reported. VO(ma)2 (log K1 = 8.80(2), log K2 = 7.51 (2), log β2 = 16.31(3)) has a rich coordination chemistry, forming a number of V(IV) and V(V) derivatives. In aqueous solution it is slowly oxidized by molecular oxygen to [VO2(ma)2]- (log K1 = 7.5(1), log K2 = 6.2(1), log β2 = 13.7(1)); in alcohols a variety of V(V) analogs VO(OR)(ma)2 (R = CH3, C2H5, i-C3H7) are formed by aerial oxidation. All these vanadate complexes can be interconverted by reaction with the appropriate alcohol or water. In addition, the six-coordinate V(IV) pyridine adduct VO(ma)2py can be formed and this undergoes oxidation to V(V) complexes much more slowly, demonstrating that a vacant coordinate site is required for the coordination of O2 to VO(ma)2 before inner-sphere oxidation can take place. 51V NMR and electrochemistry have been studied as a function of pH; a complete study of the aqueous chemistry of VO(ma)2 and [VO2(ma)2]- has been undertaken because the oral activity of VO(ma)2 as an insulinmimetic may be related to the chemical properties of the two compounds in water. Oral gavage studies in STZ-diabetic rats have been performed which showed that the intact complex is required for activity and that the presence of a biologically compatible reducing agent, ascorbic acid, neither interferes with nor augments the insulin-mimetic effect of VO(ma)2. The X-ray structures of VO(ma)2 and the cis-VO2 compound K[VO2(ma)2]·H2O have been determined; crystals of VO(ma)2 [BMOV] are monoclinic, P21/n, a = 7.366(1), b = 12.759(2), c = 13.190(1) A?, β = 97.31(1)°, Z = 4, and those of K[VO2(ma)2]·H2O are monoclinic, P21/n, a = 7.1841(9), b = 12.196(1), c = 17.147(1) A?, β = 96.64(1)°, Z = 4. The structure of VO(ma)2 was solved by direct methods and that of K[VO2(ma)2]·H2O by the Patterson method. The structures were refined by full-matrix least-squares procedures to R = 0.076 and 0.033 (R(w) = 0.075 and 0.034) for 1078 and 3232 reflections with 1 ≥ 3σ(I), respectively. VO(ma)2 forms a square pyramid with the O4 set from the two maltolato ligands in the base and the vanadyl V = O apical. [VO2(ma)2]- is roughly octahedral with a cis-[VO2]+ unit being completed by two ma- ligands. The macroscopic structure is a chain with six-coordinate K+ ions linking adjacent [VO2(ma)2]- units through coordination to the chelating ligand O atoms and water molecules.